



## Amended Appendix 3B

---

ACN 139 255 771  
ABN 82 139 255 771

Level 4, 100 Albert Road  
South Melbourne VIC 3205

**Contact:**

Phone: +61 (0)3 9692 7222  
Fax: +61 (0)3 9077 9233  
info@celamin.com

**Board of Directors:**

Martin Broome, Chairman  
Nic Clift, Non-Exec Director  
Sue-Ann Higgins, Non-Exec Director  
Tim Markwell, Director & Acting CEO

**Company Secretary:**

Melanie Leydin

**Securities on Issue:**

CNL: 3,139,298,854 ordinary shares  
CNLCA: 14,887,796 partly paid shares  
CNLOA: 859,560,939 unlisted options  
CNLOB: 13,502,498 unlisted options

Celamin Holdings NL (ASX: CNL) (*Celamin, the Company*), attaches an amended Appendix 3B to replace the Appendix 3B lodged on 10 January 2018. The previous Appendix 3B contained a minor error in the issue price.

An amended Appendix 3B is attached.

**For further information or enquiries, please contact:**

Melanie Leydin  
Company Secretary  
Celamin Holdings NL.  
T: +61 (0)3 9692 7222  
E: info@celamin.com

# Appendix 3B

## New issue announcement, application for quotation of additional securities and agreement

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12

Name of entity

CELAMIN HOLDINGS NL

ABN

82 139 255 771

We (the entity) give ASX the following information.

### Part 1 - All issues

*You must complete the relevant sections (attach sheets if there is not enough space).*

- |   |  |  |
|---|--|--|
| 1 | +Class of +securities issued or to be issued   | (a) Fully paid ordinary shares<br>(b) Fully paid ordinary shares<br>(c) Unlisted options   |
| 2 | Number of +securities issued or to be issued (if known) or maximum number which may be issued  | (a) 400,000,000 fully paid ordinary shares<br>(b) 27,004,994 fully paid ordinary shares<br>(c) 13,502,498 Unlisted options   |
| 3 | Principal terms of the +securities (eg, if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion) | (a) Fully paid ordinary shares<br>(b) Fully paid ordinary shares<br>(c) Unlisted options, expiring 10 January 2021 and exercisable at \$0.2 cents (\$0.002) per Option |

+ See chapter 19 for defined terms.

**Appendix 3B**  
**New issue announcement**

---

<p>4 Do the +securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities?</p> <p>If the additional securities do not rank equally, please state:</p> <ul style="list-style-type: none"> <li>• the date from which they do</li> <li>• the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment</li> <li>• the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</li> </ul>	<p>(a) Yes          (b) Yes          (c) No – Upon exercise of the options into fully paid ordinary shares, they will rank equally with ordinary fully paid shares on issue.</p>
<p>5 Issue price or consideration</p>	<p>(a) \$100,000 (0.025 cents per share)          (b) Deemed issue price of (\$0.003 per share)          (c) Nil</p>
<p>6 Purpose of the issue          (If issued as consideration for the acquisition of assets, clearly identify those assets)</p>	<p>(a) Tranche 1 Placement shares pursuant to the announcement dated 10 January 2018. Funds will be used by the Company to pursue enforcement of the Final Arbitration Award for recovery of its interest in the Chaketma Phosphate, other legal actions in Tunisia and for general working capital purposes.          (b) Consideration for up to 100% of outstanding director’s fees for the period 1 July 2017 to 31 December 2017, pursuant to Resolutions 4(a), 4(b), 4(c) and 4(d) as approved by shareholders at the Company’s General Meeting held on 6 July 2017.          (c) Consideration for up to 100% of outstanding director’s fees for the period 1 July 2017 to 31 December 2017, pursuant to Resolutions 4(a), 4(b), 4(c) and 4(d) as approved by shareholders at the Company’s General Meeting held on 6 July 2017.</p>
<p>6a Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A?</p> <p>If Yes, complete sections 6b – 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i</p>	<p>No</p>

---

+ See chapter 19 for defined terms.

**Appendix 3B**  
**New issue announcement**

6b	The date the security holder resolution under rule 7.1A was passed	N/A	
6c	Number of +securities issued without security holder approval under rule 7.1	(a) 400,000,000 fully paid ordinary shares	
6d	Number of +securities issued with security holder approval under rule 7.1A	N/A	
6e	Number of +securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	(b) 27,004,994 fully paid ordinary shares – 6 July 2017 (c) 13,502,498 unlisted options – 6 July 2017	
6f	Number of securities issued under an exception in rule 7.2	N/A	
6g	If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation.	N/A	
6h	If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	N/A	
7	Dates of entering +securities into uncertificated holdings or despatch of certificate	10 January 2018	
8	Number and +class of all +securities quoted on ASX (including the securities in section 2 if applicable)	Number	+Class
		3,139,298,854	Ordinary fully paid shares
		14,887,796	\$0.10 unpaid partly paid shares with first call due from 17 December 2012

+ See chapter 19 for defined terms.

**Appendix 3B**  
**New issue announcement**

---

9	Number and <sup>+</sup> class of all <sup>+</sup> securities not quoted on ASX ( <i>including</i> the securities in section 2 if applicable)	859,560,939          13,502,498	Unlisted options, expiring 11 July 2020 and exercisable at \$0.2 cents (\$0.002) per Option          Unlisted options, expiring 10 January 2021 and exercisable at \$0.2 cents (\$0.002) per Option
10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	N/A	

**Part 2 - Bonus issue or pro rata issue**

11	Is security holder approval required?	N/A	
12	Is the issue renounceable or non-renounceable?	N/A	
13	Ratio in which the <sup>+</sup> securities will be offered	N/A	
14	<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates	N/A	
15	<sup>+</sup> Record date to determine entitlements	N/A	
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A	
17	Policy for deciding entitlements in relation to fractions	N/A	
18	Names of countries in which the entity has <sup>+</sup> security holders who will not be sent new issue documents  <small>Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.</small>	N/A	
19	Closing date for receipt of acceptances or renunciations	N/A	

---

+ See chapter 19 for defined terms.

**Appendix 3B**  
**New issue announcement**

---

20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of +security holders	N/A
25	If the issue is contingent on +security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do +security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do +security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A

---

+ See chapter 19 for defined terms.

**Appendix 3B**  
**New issue announcement**

---

32 How do +security holders dispose of their entitlements (except by sale through a broker)?

33 +Despatch date

**Part 3 - Quotation of securities**

*You need only complete this section if you are applying for quotation of securities*

34 Type of securities  
(tick one)

(a)  Securities described in Part 1

(b)  All other securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

**Entities that have ticked box 34(a)**

**Additional securities forming a new class of securities**

*Tick to indicate you are providing the information or documents*

35  If the +securities are +equity securities, the names of the 20 largest holders of the additional +securities, and the number and percentage of additional +securities held by those holders

36  If the +securities are +equity securities, a distribution schedule of the additional +securities setting out the number of holders in the categories  
1 - 1,000  
1,001 - 5,000  
5,001 - 10,000  
10,001 - 100,000  
100,001 and over

37  A copy of any trust deed for the additional +securities

**Entities that have ticked box 34(b)**

38 Number of securities for which +quotation is sought

39 Class of +securities for which quotation is sought

---

+ See chapter 19 for defined terms.

<p>40 Do the +securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities?</p> <p>If the additional securities do not rank equally, please state:</p> <ol style="list-style-type: none"> <li>1. the date from which they do</li> <li>2. the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment</li> <li>3. the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</li> </ol>	
--	--

<p>41 Reason for request for quotation now</p> <p>Example: In the case of restricted securities, end of restriction period</p> <p>(if issued upon conversion of another security, clearly identify that other security)</p>	
---	--

<p>42 Number and +class of all +securities quoted on ASX (including the securities in clause 38)</p>	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 50%;">Number</th> <th style="width: 50%;">+Class</th> </tr> <tr> <td style="height: 80px;"></td> <td></td> </tr> </table>	Number	+Class			
Number	+Class					

+ See chapter 19 for defined terms.



**Appendix 3B**  
**New issue announcement**

---

**Quotation agreement**

1 +Quotation of our additional +securities is in ASX's absolute discretion. ASX may quote the +securities on any conditions it decides.

2 We warrant the following to ASX.

- The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
- There is no reason why those +securities should not be granted +quotation.
- An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.
- If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.

3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

4 We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.



Sign here .....  
(Company secretary)

Date: 10 January 2018

Print name: Melanie Leydin

== == == == ==

---

+ See chapter 19 for defined terms.

## Appendix 3B – Annexure 1

Celamin Holdings NL is not an eligible entity in accordance with ASX Listing Rule 7.1A and as such has not completed the Annexure.